^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RPL22L1 overexpression

i
Other names: RPL22L1, Ribosomal Protein L22 Like 1, Large Ribosomal Subunit Protein EL22-Like 1, 60S Ribosomal Protein L22-Like 1, Ribosomal Protein L22-Like 1
Entrez ID:
Twitter
Trials
5ms
Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. (PubMed, Cell Death Discov)
Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients.
Journal
|
RPL22L1 (Ribosomal Protein L22 Like 1)
|
RPL22L1 overexpression
|
sorafenib
6ms
Long-Read Nanopore Sequencing Identifies Mismatch Repair-Deficient Related Genes with Alternative Splicing in Colorectal Cancer. (PubMed, Dis Markers)
Our results showed that ONT-identified genes provide a pool to explore AS-associated markers for dMMR/MSI CRC. We demonstrated INHBA as a promising signature for clinical application in predicting tumor lymphatic metastasis and screening dMMR/MSI candidates.
Journal • Mismatch repair
|
MSI (Microsatellite instability) • RPL22L1 (Ribosomal Protein L22 Like 1) • HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2)
|
MSI-H/dMMR • RPL22L1 overexpression